Bladder Cancer – Topic Hub

Explore Grand Rounds in Urology talks categorized Bladder Cancer.

Sort by Disease State / Sort by Treatment and Special Topics

Sort by Disease State

TitleSpeakerDisease StateSubstageRisk CategoryBCG StatusLine of TherapySystemic Eligibility
Beyond Symptom Management: Exploring Hydration as a Proactive Strategy to Improve the INLEXZO™ Patient ExperienceSiamak Daneshmand, MD2026Bladder Cancer, NMIBCCISSalvage
Advanced Disease SequencingDaniel P. Petrylak, MD2026Bladder CancerInitial
Top 10 ASTRO 2025 Studies: Prostate and Bladder Cancer HighlightsSherief H. Gamie, MD, PhD2026
Bladder Preservation vs. CystectomyDaniel P. Petrylak, MD2026Bladder Cancer, MIBC
Why Biomarkers Matter NowAdam Cole, MD, FS2026Bladder Cancer
Highlights of AUA, GU ASCO, ASCO, and ASTROHanan Goldberg, MD, MSc2026Bladder Cancer, Prostate Cancer, Renal Cancer
BCG-Unresponsive NMIBCDaniel P. Petrylak, MD2026Bladder Cancer, NMIBCHigh
Implementing New Bladder Cancer Therapies in Urology PracticeMark N. Painter, CPMA, MBS2026Bladder Cancer
INLEXZO™ (Gem iDRS) Reimbursement UpdateMark N. Painter, CPMA, MBS2026Bladder Cancer
Integrating INLEXZO™ Into Community Urology Practice: Workflow, Patient Selection, and ImplementationScott B. Sellinger, MD, FACS2026Bladder Cancer, NMIBCTa, T1, CISHighRefractory
Optimizing Patient Management for INLEXZO™ in BCG-Unresponsive Non-Muscle Invasive Bladder CancerSam S. Chang, MD, MBA2026Bladder Cancer, NMIBC
TARA-002 Shows Early Promise for High-Risk NMIBC in the ADVANCED-2 Phase 2 TrialE. David Crawford, MD2026Bladder Cancer, NMIBC
Virtual Bladder Cancer Staging: Imaging Strategies to Reduce the Burden of TURBTJodi K. Maranchie, MD, FACS2026Bladder Cancer, NMIBCTa, T1, T2Low, HighInitial
Intravesical Drug Delivery System (Gem-iDRS) in NMIBCSiamak Daneshmand, MD2026NMIBCTa, T1, CISHighUnresponsiveRefractory
Management of High Risk NMIBC—What’s New in Intravesical TherapyJodi K. Maranchie, MD, FACS2026NMIBCT1, CISHighExposed, Unresponsive
Beyond Cancer: Breaking Down Bladder Cancer SurvivorshipJennifer Gomez, MMS, PA-C2025NMIBCTa, T1, CIS, T2Low, HighInitial
Session 4 Panel DiscussionTyler F. Stewart, MD2025NMIBCT1, CIS, T2, T3–T4HighUnresponsiveRefractoryCisplatin-Eligible, Cisplatin-Ineligible
Metastatic Bladder Cancer: Novel TherapiesTian Zhang, MD, MHS, FASCO2025MetastaticT3–T4Salvage, RefractoryCisplatin-Eligible
Case PresentationShilpa Gupta, MD2025MIBCT2, T3–T4HighInitial, SalvageCisplatin-Eligible, Cisplatin-Ineligible
Neoadjuvant and Adjuvant Treatment for the Management of Upper Tract DiseaseShilpa Gupta, MD2025T2, T3–T4HighCisplatin-Eligible, Cisplatin-Ineligible
Management of Upper Tract Urothelial CarcinomaYair Lotan, MD2025MIBCTa, T1, T2, T3–T4LowInitialCisplatin-Eligible, Cisplatin-Ineligible
Upper Tract versus Lower Tract: Is There a Biological Difference?Donna E. Hansel, MD, PhD2025MIBCTa, T1, T2, T3–T4HighInitial
Case PresentationSima P. Porten, MD, MPH, FACS2025MIBCT2HighSalvageCisplatin-Eligible
Future Role for Local Therapy Following Successful Treatment of Metastatic Urothelial CarcinomaNima Almassi, MD2025MetastaticT2, T3–T4HighSalvageCisplatin-Eligible, Cisplatin-Ineligible
Bladder Preservation: Post-Chemotherapy Immunotherapy for MIBCSima P. Porten, MD, MPH, FACS2025MIBCT2, T3–T4HighInitialCisplatin-Eligible, Cisplatin-Ineligible
Combined Modality Therapy for Localized Urothelial CarcinomaAmirali Salmasi, MD, MSCR2025MIBCT2, T3–T4HighInitial
Session 4 Panel Discussion: Radical Surgical Approaches to Bladder CancerBernard H. Bochner, MD, FACS2025Bladder Cancer, NMIBCTa, T1, CIS, T2, T3–T4Intermediate, HighNaïve, Exposed, UnresponsiveInitial, Salvage, RefractoryCisplatin-Eligible, Cisplatin-Ineligible
Surgical Quality, Urinary Diversion, and QOL Considerations for Invasive Bladder CancerBernard H. Bochner, MD, FACS2025MIBCT2, T3–T4HighInitial
Case PresentationRobert Dreicer, MD, MS, MACP, FASCO2025
Session 1 Panel Discussion: Pathology, Etiology, and Diagnosis of Urothelial CancerYair Lotan, MD2025
Adjuvant Therapy for Muscle-Invasive Urothelial CarcinomaGuru P. Sonpavde, MD2025MIBCT2, T3–T4HighInitialCisplatin-Eligible, Cisplatin-Ineligible
Intermediate Risk: Differences in Trial Designs Compared to High-Risk Disease, Comparisons, and Justifying ToxicityVignesh T. Packiam, MD2025NMIBCTa, T1, CISIntermediateNaïve, UnresponsiveInitial, Refractory
INLEXZO™ J Code UpdateDavid S. Morris, MD, FACS2026NMIBCCISHighUnresponsiveRefractory
First-Line Therapy for Metastatic Locally Unresectable Urothelial CarcinomaDaniel P. Petrylak, MD2025MetastaticT3–T4InitialCisplatin-Eligible, Cisplatin-Ineligible
Selection and Sequencing: Optimizing Therapy for Relapsed/Refractory Metastatic Urothelial CancerArlene O. Siefker-Radtke, MD2025MetastaticSalvage, RefractoryCisplatin-Eligible, Cisplatin-Ineligible
Neoadjuvant Therapy: State-of-the-Art, Selection of Regimen, and Future TherapyGopakumar V. Iyer, MD2025MIBCT2, T3–T4HighInitialCisplatin-Eligible, Cisplatin-Ineligible
Bladder Sparing Strategies: Preserving Organ Function While Ensuring Oncologic ControlBrent Rose, MD2025
Perioperative Systemic Therapy Adjuvant IO: Integrating Systemic Treatments with Surgical ManagementNicolaos J. Palaskas, MD, PhD2025
How to Move Ahead in BCG-Unresponsive Disease: Selecting Initial Treatment, Sequences, and When is Enough Enough?Piyush K. Agarwal2025NMIBCTa, T1, CISHighUnresponsiveSalvage, Refractory
Therapeutic Perioperative Decision-Making for Muscle-Invasive Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2025MIBCT2, T3–T4HighInitialCisplatin-Eligible, Cisplatin-Ineligible
Improving Sexual Functional Outcomes In MIBC-Nerve Sparing, Organ Preservation, and Other Quality Of Life ConsiderationsJohn W. Tillett, MD, FACS2025MIBCT2, T3–T4HighInitial
Frontline Systemic Treatment for Metastatic Disease: Optimizing First-Line Systemic Approaches for Advanced Urothelial CancerNicolaos J. Palaskas, MD, PhD2025
Gender Disparities in the Diagnosis of Urothelial CarcinomaDonna E. Hansel, MD, PhD2025MIBCT1, CIS, T2, T3–T4HighInitial
High-Risk NMIBC: Is BCG Still the Best Option?Neal D. Shore, MD, FACS2025NMIBCTa, T1, CISHighNaïveInitial
The Role of White Light Enhancements and AI-Based CystoscopyYair Lotan, MD2025NMIBCTa, T1, CIS, T2Low, HighInitial, Salvage
Molecular Changes in Bladder CancerDonna E. Hansel, MD, PhD2025MIBCTa, T1, CIS, T2, T3–T4HighInitial
Biomarkers For Localized Disease: Are Molecular Predictive Markers Ready For Prime-Time Therapy Decisions?Tyler F. Stewart, MD2025
Intravesical Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC): Innovative Approaches to Preventing Progression and RecurrenceAmirali Salmasi, MD, MSCR2025NMIBCTa, T1, CISIntermediate, HighNaïve, UnresponsiveInitial, Refractory
Perioperative Chemotherapy for Upper Tract Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2025
Current State of Neoadjuvant Chemotherapy in Urothelial CancersBenjamin W. Rush, MD2025
Perioperative Systemic Therapy: Perioperative ImmunotherapyTyler F. Stewart, MD2025
Therapies Beyond BCG for NMIBCBrant A. Inman, MD, MS, FRCSC2025
Bladder Sparing Methods in Muscle-Invasive Bladder CancerBrant A. Inman, MD, MS, FRCSC2025
Management of Muscle-Invasive Bladder Cancer: Paradigm Shift?Robert Dreicer, MD, MS, MACP, FASCO2025
Microbiome in Bladder CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Future of PathologyAdam Cole, MD, FS2025
Immunotherapy for Bladder CancerSteven E. Finkelstein, MD, DABR, FACRO2025
Microbiome and CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Bladder Sparing Tri-Modality Therapy Updates 2025Daniel A. Hamstra, MD, PhD, FASTRO, FASCO2025
What’s in the Pipeline for Bladder Cancer Management in 2026?Seth P. Lerner, MD, FACS2025
Urodynamics With and Without the Use of FluoroscopyMary Y. Wang, DNP, CRNP2025
Bladder Cancer Risk Factors and PrevalenceAnne E. Lizardi, DNP, CRNP, RNFA2025
Bladder Cancer Current Treatment LandscapeAnne E. Lizardi, DNP, CRNP, RNFA2025
Bladder Cancer Evaluation and DiagnosisAnne E. Lizardi, DNP, CRNP, RNFA2025
WSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation StudyWayne G. Brisbane, MD2025
Prostate Cancer Detection Biomarkers, MRIAdam S. Kibel, MD2025
Role of Immunotherapy for Upper Tract UCGopakumar V. Iyer, MD2024
Bladder Cancer Journal Vol. 11, Issue 2 - April - June 2025Bladder Cancer Journal2025
Role of DNA Repair Mutations in Sensitivity to Cisplatin-based ChemotherapyGopakumar V. Iyer, MD2024
Grade Group 1 at Biopsy - Do We Need to Know More?John W. Davis, MD, FACS2025
Updates to Microhematuria: AUA and SUFU Guidelines Update 2025Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD2025
Neoadjuvant Chemo vs. I/0 vs. ADCsDaniel P. Petrylak, MD2024
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate CancerSteven J. Frank, MD, FACR, FABS, FASTRO2025
Intermediate-Risk NMIBC/BCG Naïve: Treatment of ChoiceLeonard G. Gomella, MD, FACS2025
Bladder Cancer Journal Vol. 11, Issue 1 - January - March 2025Bladder Cancer Journal2025
High-Risk/BCG Naïve: Treatment of ChoiceMichael A. O'Donnell, MD, FACS2024
Bladder Cancer Biomarkers: SurveillanceYair Lotan, MD2024
Highlights of NCCN/AUA Guidelines 2024Siamak Daneshmand, MD2024
Role of Systemic Therapies in NMIBCAmirali Salmasi, MD, MSCR2024
Role of CtDNA in Bladder CancerAlexandra Drakaki, MD, PhD2024
Role of PLND for High Risk Bladder CancerBernard H. Bochner, MD, FACS2024
Erdafitinib Update - Metastatic Urothelial CancerDaniel P. Petrylak, MD2024
UTUC Staging, Diagnosis, Intraureteralpelvis Therapy, Endoscopic ManagementJennifer A. Linehan, MD2024
BCG Unresponsive Intravesical TherapyPiyush K. Agarwal2024
Perioperative Chemotherapy for Upper Tract Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2024
Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder CancerParminder Singh, MD2024
Counterpoint: Radical Cystectomy for Muscle Invasive Bladder CancerJuan J. Chipollini, MD, FACS2024
Point: Bladder Sparing Approach for Muscle Invasive Bladder CancerParminder Singh, MD2024
Immunotherapy in Prostate CancerSandy Srinivas, MD2024
Clinical Trials in MIBC and NMIBCDaniel P. Petrylak, MD2024
Updates in Radiotherapy for Bladder CancerDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2024
Updates in Advanced Urothelial CarcinomaNeda Hashemi, MD, FACOG2024
The Bespoke Future of Cancer CareLeonard G. Gomella, MD, FACS2024
Recurrent T1HG Bladder cancer after BCG: More Intravesical Therapy or Radical CystectomyFrances M. Alba, MD2024
Current State of the Art in Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder CancerJason A. Efstathiou, MD, DPhil2024
Updates on the Imaging for Urothelial CarcinomaDesencia E. Thomas, MD2024
Utilizing ctDNA in Bladder CancerLeonard G. Gomella, MD, FACS2024
Current Management of T1 High Grade Bladder CancerFrances M. Alba, MD2024
The Making of the Ileal Orthotopic Bladder Substitute with an Afferent Tubular Segment: In Memory of Prof. Urs StuderFiona C. Burkhard, MD2024
Innovations in Bladder Cancer: Strategies for Improving Outcomes Across the Disease ContinuumDaniel P. Petrylak, MD2024
Bladder Cancer Journal Vol. 10, Issue 2Bladder Cancer Journal2024
Therapy for High Risk NMIBCColin P. N. Dinney, MD2023
Imaging and Biomarkers in Patient Selection for Focal AblationEzekiel Becher, MD2024
Updates on the Latest Classifications of Urothelial CancersFrancisco G. La Rosa, MD2024
Obstacles to Optimal Outcomes for Patients Undergoing Radical CystectomyRaj S. Pruthi, MD, MHA, FACS2022
UPJO Management: Cut, Construct, or CheckBenjamin K. Canales, MD, MPH2023
Emergent Applications of Prostate Cancer Mapping with Artificial IntelligenceAlan Priester, PhD2024
Clinical Evaluation and Management of Men with Localized and Recurrent Prostate CancerJan Philipp Radtke, MD, MBA2024
Clinical Trial of STHLM3 and MRITobias Nordstrom, MD, PhD2024
Prostate Cancer Screening Practices in EuropeMonique Roobol, PhD, MSc2024
NCCN Guidelines for Early Detection of Prostate Cancer 2023Preston C. Sprenkle, MD2024
Multi-modality (MRI+PET) Imaging for Improved Detection of csPCDavid Margel, MD, PhD2024
PSMA in Metastatic Prostate Cancer: Imaging as BiomarkerLouise Emmett, MD, FAANMS, FRACP, MBChB2024
Precision Diagnostics and Emerging Treatment StrategiesDavid M. Nanus, MD2024
Novel Targeted Treatment and Its Integration with Precision DiagnosticsDaniel P. Petrylak, MD2024
Micro-ultrasound and MRI for Visualization of Prostate CancerWayne G. Brisbane, MD2024
Bladder Cancer Journal Vol. 10, Issue 1Bladder Cancer Journal2024
Bladder Cancer Journal Vol. 9, Issue 4Bladder Cancer Journal2023
Diagnosing Renal Masses: Do Advanced Imaging Techniques and Biomarkers Play an Important Role?Justin J. Badal, MD2023
Bladder Cancer Journal Vol. 9, Issue 3Bladder Cancer Journal2023
Bladder Cancer Journal Vol. 9, Issue 2Bladder Cancer Journal2023
Role of Circulating Tumor DNA and Adjuvant Therapy in Urothelial CarcinomaTyler F. Stewart, MD2023
Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery - ProT. Mike Hsieh, MD, MBA2023
NMIBC Trials for BCG Naive Patients: What is ExcitingJoshua J. Meeks, MD, PhD2022
Neoadjuvant or Adjuvant Therapy?Parminder Singh, MD2022
Fusion-guided Ablation with Koelis ProMap-FTNiranjan Nayar, MHA2023
Neoadjuvant Therapy for MIBC in the Genomic EraColin P. N. Dinney, MD2023
Open vs Robotic Cystectomy for Bladder CancerColin P. N. Dinney, MD2023
Earlier Use of Immune Checkpoint Inhibitors to Adjuvant and NMIBC: What Do We Do About Patients for Reinduction of Immune TreatmentGuru P. Sonpavde, MD2022
Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to DoSeth P. Lerner, MD, FACS2022
Use of the Cxbladder Monitor Urine Genomics Test for Surveillance of Patients with Non-Muscle-Invasive Bladder CancerDaniel Shoskes, MD, MSc, FRCSC2022
Bladder Cancer Journal Vol. 9, Issue 1Bladder Cancer Journal2023
Bladder Cancer Risk Stratification: Moving from the Old to the NewJoshua J. Meeks, MD, PhD2022
Controversies in NMIBC: Guidelines and BeyondSam S. Chang, MD, MBA2022
Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?Peter Black, MD, FACS, FRCSC2022
The Contribution of SWOG to Bladder Cancer Clinical TrialsSeth P. Lerner, MD, FACS2022
Risk-Adapted TURBTSeth P. Lerner, MD, FACS2022
Bladder Sparing Tri-Modal Therapy UpdatesDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2022
Obstacles to Optimal Outcomes for Patients Undergoing Radical CystectomyRaj S. Pruthi, MD, MHA, FACS2023
Immune Checkpoint InhibitorsDaniel P. Petrylak, MD2022
Bladder Cancer Journal Vol. 8, Issue 4Bladder Cancer Journal2022
Enhanced Techniques of NMIBC DetectionMark D. Tyson II, MD, MPH2022
Use of Biomarkers in NMIBC: What’s New and What Should We Use?Peter Black, MD, FACS, FRCSC2022
Biomarker Integration for Advanced Urothelial CarcinomaDonna E. Hansel, MD, PhD2022
Pathology of Urothelial CancersDonna E. Hansel, MD, PhD2022
What Should I Do About Micropapillae? Do I Treat it Differently than Standard?Donna E. Hansel, MD, PhD2022
Methods and Guidelines to Stage and Grade (Low vs. High) UTUC and How Should We TreatSeth P. Lerner, MD, FACS2022
FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial CancerParminder Singh, MD2022
Targeted Therapy Combined with Immune Checkpoint Therapy: Is This the Wave of the Future?Jean Heather Hoffman-Censits, MD2022
High Risk and Advanced Upper Tract Urothelial Carcinoma – Still a Role for SurgeryJennifer A. Linehan, MD2022
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the FutureJennifer A. Linehan, MD2022
Immune Checkpoint Inhibitors: Combination TherapyJean Heather Hoffman-Censits, MD2022
Immune Checkpoint Inhibitors: Managing Immune-related Side EffectsGuru P. Sonpavde, MD2022
The Use of Antibody-drug Conjugates in Treating Advanced Urothelial CancerDaniel P. Petrylak, MD2022
UTUC Is it Biologically DistinctDonna E. Hansel, MD, PhD2022
Industry Perspective - From Science to Clinical Utility: The Role of Cxbladder in the Diagnosis and Management of Bladder CancerTamer Aboushwareb, MD, PhD2022
Bladder Cancer Journal Vol. 8, Issue 3Bladder Cancer Journal2022
Bladder Cancer Journal Vol. 8, Issue 2Bladder Cancer Journal2022
Non-Muscle Invasive Bladder Cancer: Guidelines-Based ApproachRaj S. Pruthi, MD, MHA, FACS2022
Point-Counterpoint: Neoadjuvant Chemotherapy Prior to Cystectomy (Pro)Amirali Salmasi, MD, MSCR2022
Point-Counterpoint: Neoadjuvant Chemotherapy Prior to Cystectomy - ConAlan H. Bryce, MD2022
Updating the Definitions, Endpoints, and Clinical Trial Designs for Bladder CancerAmirali Salmasi, MD, MSCR2022
Bladder Cancer Journal Vol. 8, Issue 1Bladder Cancer Journal2022
When is Radical Cystectomy Indicated for NMIBC?Guilherme Godoy, MD, MS2022
Bladder-Sparing Trimodality TherapyDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2022
Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder CancerAmirali Salmasi, MD, MSCR2022
Industry Perspective: Developing the Most Sensitive Urine Test for Bladder CancerNam W. Kim, PhD2022
Managing NMIBC in the BCG Shortage EraSeth P. Lerner, MD, FACS2022
Neoadjuvant vs. Adjuvant vs. None - "Perioperative Therapy"A. Edward Yen, MD2022
Bladder Cancer Journal Vol. 7, Issue 4Bladder Cancer Journal2021
Panel Discussion – Focus on PSMAPhillip J. Koo, MD2021
Bladder Cancer Journal Vol. 7, Issue 3Bladder Cancer Journal2021
Current Status of PSMA DiagnosticsJérémie Calais, MD, PhD2021
Next Generation Imaging for Prostate CancerPhillip J. Koo, MD2021
Deciphering the Changing Landscape of Differential Delay in Cancer Diagnoses in Community Radiation and Medical OncologyMitchell O. Finkelstein2021
Urine Biomarkers for the Detection of Urothelial CarcinomaSiamak Daneshmand, MD2021
Blue Light vs. White Light Cystoscopy for NMIBCSanjay G. Patel, MD2021
A Review of AUA / SUO / ASTRO Guidelines for MIBCMichael S. Cookson, MD, MMHC2021
Bladder Cancer Journal Vol. 7, Issue 2Bladder Cancer Journal2021
Industry Perspective: The Role of URO17 â„¢ in the Diagnosis and Management of Bladder CancerJohn Cucci2021
Industry Perspective: Panel Discussion on Cxbladder Genomic Urine Test for Bladder CancerSiamak Daneshmand, MD2021
Bladder Cancer Journal Vol. 7, Issue 1Bladder Cancer Journal2020
Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder CancerRobert Dreicer, MD, MS, MACP, FASCO2021
Neoadjuvant Immune-Checkpoint Inhibition for Muscle-Invasive Bladder CancerPetros Grivas, MD, PhD2021
Bladder Cancer Journal Vol. 6, Issue 4Bladder Cancer Journal2020
Immunotherapy For Muscle Invasive Bladder CancerA. Edward Yen, MD2020
Bladder Cancer Journal Vol. 6, Issue 3Bladder Cancer Journal2020
PC Markers AlgorithmE. David Crawford, MD2020
Updates in Muscle Invasive Bladder CancerSiamak Daneshmand, MD2020
The First Tissue Engineered Neo-Urinary Conduit (NUC) Clinical Trial for Complete Organ Replacement: Successes, Pitfalls, ChallengesTrinity J. Bivalacqua, MD, PhD2020
Blue Light Cystoscopy: How Does It Fit into the Non-Muscle Invasive Bladder Cancer Guidelines?Jeffrey M. Holzbeierlein, MD2020
Bladder Cancer Journal Vol. 6, Issue 2Bladder Cancer Journal2020
ERAS Pathways in Radical CystectomyJeffrey M. Holzbeierlein, MD2020
Management of High-Grade T1 Bladder CancerJeffrey M. Holzbeierlein, MD2020
The Role of Immunonutrition in Bladder Cancer & the SIMMUNE Trial (S1600)Jeffrey M. Holzbeierlein, MD2020
Adaptive Immune Resistance to Intravesical BCG in NMIBC: Implications for Ongoing and Future BCG Unresponsive Clinical TrialsTrinity J. Bivalacqua, MD, PhD2020
Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder CancerJeffrey M. Holzbeierlein, MD2020
Bladder Cancer Journal Vol. 6, Issue 1Bladder Cancer Journal2020
BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder CancerDonald L. Lamm, MD, FACS2019
Robotic Cystectomy and ICUD for Muscle Invasive Bladder CancerSanjay G. Patel, MD2019
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial CarcinomaDaniel P. Petrylak, MD2020
FDA Approves Pembrolizumab for New Indication of NMIBCDaniel P. Petrylak, MD2020
Bladder Cancer Journal Vol. 5 Issue 4Bladder Cancer Journal2019
ESMO: Astellas, Seattle Genetics' Keytruda Combo Shrinks 71% of Bladder CancersDaniel P. Petrylak, MD2019
Bladder Cancer Journal Vol. 5 Issue 3Bladder Cancer Journal2019
Case-Based Panel Discussion: Muscle-Invasive Bladder CancerJennifer M. Taylor, MD, MPH2019
Prevalence of Criteria for Genetic Testing According to the National Comprehensive Cancer Network Guidelines in a Contemporary Cohort of Post-Prostatectomy Men with Intermediate and High-Risk Prostate Cancer: The Henry Ford Health System ExperienceDavid Utz2019
Case-Based Panel Discussion: Non-Muscle Invasive Bladder CancerJennifer M. Taylor, MD, MPH2019
Bladder Cancer Journal Vol. 5 Issue 2David Utz2019
Live-Primary Cell Phenotypic Biomarkers and Prostate Cancer PrognosisDavid M. Albala, MD2019
PT0 after NAC: Implications for Bladder Sparing and PrognosisLeonard G. Gomella, MD, FACS2019
Management of Adverse Pathology after Radical ProstatectomyJason A. Efstathiou, MD, DPhil2019
The Gold Standard for Bladder Cancer DetectionNeal D. Shore, MD, FACS2019
Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard?Seth P. Lerner, MD, FACS2019
Lymphadeneactomy in Invasive Bladder Cancer: Knowns and UnknownsSeth P. Lerner, MD, FACS2019
BCG Maintenance Should Be Less IntenseMichael S. Cookson, MD, MMHC2018
Debate: Neoadjuvant Chemotherapy Prior to Cystectomy | Con ArgumentMichael S. Cookson, MD, MMHC2018
Debate: Neoadjuvant Chemotherapy Prior to Cystectomy | Pro ArgumentDaniel P. Petrylak, MD2018
Thromboembolic Complications in Bladder CancerLeonard G. Gomella, MD, FACS2019
T1 Bladder CancerSeth P. Lerner, MD, FACS2019
Checkpoint Inhibitors for NMIBCDaniel P. Petrylak, MD2018
Can MR Imaging Help Triage Bladder Cancer Patients?John C. Chang, MD, PhD2018
Targeted Therapy for the Treatment of Advanced/Metastatic Urothelial CancerDaniel P. Petrylak, MD2019
Urinary Markers in NMIBC: What’s New?Sanjay G. Patel, MD2019
BCG Unresponsive DiseaseSanjay G. Patel, MD2019
Bladder Cancer Journal Vol. 5 Issue 1Bladder Cancer Journal2019
Bladder Cancer and ImmunotherapyJennifer M. Taylor, MD, MPH2018
Lymph Node Dissection During Radical Cystectomy – Current State of the ArtSeth P. Lerner, MD, FACS2018
Case Based Decision-Making for Treatment of MIBCSeth P. Lerner, MD, FACS2018
Bladder Cancer Journal Vol. 4 Issue 4Bladder Cancer Journal2018
Second-line Bladder Cancer Therapies When First Line Treatments FailJennifer M. Taylor, MD, MPH2018
Controversies in Non-Muscle Invasive Bladder CancerSiamak Daneshmand, MD2018
Updates on Immunotherapy for Bladder CancerDaniel P. Petrylak, MD2018
A Biodynamic Imaging Platform for Bladder CancerJeff Fensterer2018
Bladder Cancer Journal Vol. 4 Issue 3Bladder Cancer Journal2018
En Bloc TURB - More Than a Safe and Feasible Surgical TechniqueSalvatore Micali, MD2018
Bladder Cancer Journal Vol. 4 Issue 2Bladder Cancer Journal
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United StatesBladder Cancer Journal2018
Bladder Cancer Genetic Susceptibility. A Systematic ReviewBladder Cancer Journal2018
The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder CancerBladder Cancer Journal2018
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological VariantsBladder Cancer Journal2018
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional StudyBladder Cancer Journal2018
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell LinesBladder Cancer Journal2018
Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and PreventionBladder Cancer Journal2018
Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical CystectomyBladder Cancer Journal2018
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging TherapiesBladder Cancer Journal2018
Advanced Disease — A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2018
New Targets for Advanced Bladder CancerDaniel P. Petrylak, MD2018
Should Variant Histology Change Management of Bladder Cancer?Peter Black, MD, FACS, FRCSC2018
Neoadjuvant/ Adjuvant Chemotherapy—Are We Ready to Accept Neoadjuvant as the Gold Standard?Seth P. Lerner, MD, FACS2018
Basic Concepts in Bladder Cancer ImmunotherapyLeonard G. Gomella, MD, FACS2018
Basic Science Foundations of Bladder Cancer Diagnosis and TreatmentDan Theodorescu, MD, PhD2018
New Targets for the Treatment of Urothelial CancerDaniel P. Petrylak, MD2018
Perioperative Pathways: What We Know WorksPeter Black, MD, FACS, FRCSC2018
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelinesSam S. Chang, MD, MBA2018
BCG Unresponsive Disease: A Roadmap for Drug Development and Integration of Novel TherapiesSeth P. Lerner, MD, FACS2018
Enhanced Techniques of Non-Muscle Invasive Bladder Cancer DetectionMichael S. Cookson, MD, MMHC2018
Urine Markers for Bladder CancerPeter Black, MD, FACS, FRCSC2018
Robotic Cystectomy Versus Open Cystectomy: What Do We Know?Sam S. Chang, MD, MBA2018
Barriers to Clinical Trials for Non-Muscle Invasive Bladder CancerAshish M. Kamat, MD, MBBS2018
Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder CancerBladder Cancer Journal2018
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-AnalysisBladder Cancer Journal2018
Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder CancerBladder Cancer Journal2018
Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7Bladder Cancer Journal2018
Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and EnablersBladder Cancer Journal2018
Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T MutationBladder Cancer Journal2018
Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic ReviewBladder Cancer Journal2018
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder CancerBladder Cancer Journal2018
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder CancerBladder Cancer Journal2018
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder CancerBladder Cancer Journal2018
Perioperative Management of the Radical Cystectomy PatientErik P. Castle, MD, FACS2017
Immunotherapeutic Agents in Metastatic Bladder CancerAlan H. Bryce, MD2017
Can the DECIPHER Marker Predict Chemotherapy?Robert Abouassaly, MD, MS2017
The DECIPHER Marker Can Predict ChemotherapyAlan H. Bryce, MD2017
BCG Failure: BCG Maintenance Should be Less IntenseMichael S. Cookson, MD, MMHC2017
BCG Maintenance - Full SWOG Course - Pro ArgumentErik P. Castle, MD, FACS2017
Difficult Issues in Non Muscle Invasive Bladder CancerMichael S. Cookson, MD, MMHC2017
BCG Failure: Defining and Managing Difficult PatientsMichael S. Cookson, MD, MMHC2017
Urinary Molecular Marker Tests in Bladder Cancer: An Overview of CxbladderSiamak Daneshmand, MD2017
Prevalence of Clostridium Difficile Infection in Patients After Radical Cystectomy and Neoadjuvant ChemotherapyBladder Cancer Journal2017
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder CancerBladder Cancer Journal2017
Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data BaseBladder Cancer Journal2017
Bladder Cancer Recovery Pathways: A Systematic ReviewBladder Cancer Journal2017
Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder CancerBladder Cancer Journal2017
Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder CancerBladder Cancer Journal2017
Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?Bladder Cancer Journal2017
Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the LiteratureBladder Cancer Journal2017
Quality Indicators in Radical CystectomySeth P. Lerner, MD, FACS2017
Perioperative Pathways: What We Know WorksPeter Black, MD, FACS, FRCSC2017
Thromboembolic Complications in Bladder CancerJehonathan H. Pinthus, MD, PhD, FRCSC2017
Robotic Cystectomy Versus Open Cystectomy: Do We Really Need to Discuss?Sam S. Chang, MD, MBA2017
Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder CancerDaniel P. Petrylak, MD2017
Precision Medicine and Advanced Bladder Cancer: Where Are We Today?Dan Theodorescu, MD, PhD2017
Checkpoint InhibitorsDaniel P. Petrylak, MD2017
Neoadjuvant and Adjuvant Chemotherapy in Bladder CancerNeal D. Shore, MD, FACS2017
Basic Science in Bladder Cancer: What a Practicing Urologist Needs to Know in 2017Dan Theodorescu, MD, PhD2017
BCG Unresponsive Non-Muscle Invasive Bladder CancerSeth P. Lerner, MD, FACS2017
Enhanced Technique Endoscopic Visualization in NMIBCMichael S. Cookson, MD, MMHC2017
Urine Markers for Bladder CancerPeter Black, MD, FACS, FRCSC2017
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelinesSam S. Chang, MD, MBA2017
Biomarkers in Genitourinary CancersE. David Crawford, MD2015
Bladder Cancer: Advances in Diagnosis and Clinical CareSeth P. Lerner, MD, FACS2015

Sort by Treatment and Special Topics

TitleSpeakerPrimary-topicTreatment-typeSpecial-topicDisease State
Beyond Symptom Management: Exploring Hydration as a Proactive Strategy to Improve the INLEXZO™ Patient ExperienceSiamak Daneshmand, MD2026Intravesical TherapyBladder Cancer, NMIBC
Advanced Disease SequencingDaniel P. Petrylak, MD2026Systemic TherapyChemotherapy, Immunotherapy, ADCMolecular ProfilingBladder Cancer
Top 10 ASTRO 2025 Studies: Prostate and Bladder Cancer HighlightsSherief H. Gamie, MD, PhD2026
Bladder Preservation vs. CystectomyDaniel P. Petrylak, MD2026Bladder Preservation, Clinical TrialsBladder Cancer, MIBC
Why Biomarkers Matter NowAdam Cole, MD, FS2026Imaging & DiagnosticsMolecular ProfilingBladder Cancer
Highlights of AUA, GU ASCO, ASCO, and ASTROHanan Goldberg, MD, MSc2026Clinical TrialsBladder Cancer, Prostate Cancer, Renal Cancer
BCG-Unresponsive NMIBCDaniel P. Petrylak, MD2026Systemic Therapy, Intravesical TherapyImmunotherapyBladder PreservationBladder Cancer, NMIBC
Implementing New Bladder Cancer Therapies in Urology PracticeMark N. Painter, CPMA, MBS2026Systemic Therapy, Intravesical TherapyBladder Preservation, Clinical TrialsBladder Cancer
INLEXZO™ (Gem iDRS) Reimbursement UpdateMark N. Painter, CPMA, MBS2026Bladder Cancer
Integrating INLEXZO™ Into Community Urology Practice: Workflow, Patient Selection, and ImplementationScott B. Sellinger, MD, FACS2026Systemic Therapy, Intravesical TherapyBladder Preservation, Clinical TrialsBladder Cancer, NMIBC
Optimizing Patient Management for INLEXZO™ in BCG-Unresponsive Non-Muscle Invasive Bladder CancerSam S. Chang, MD, MBA2026Intravesical TherapyBladder Cancer, NMIBC
TARA-002 Shows Early Promise for High-Risk NMIBC in the ADVANCED-2 Phase 2 TrialE. David Crawford, MD2026ImmunotherapyClinical TrialsBladder Cancer, NMIBC
Virtual Bladder Cancer Staging: Imaging Strategies to Reduce the Burden of TURBTJodi K. Maranchie, MD, FACS2026Intravesical Therapy, SurveillanceMolecular Profiling, Clinical TrialsBladder Cancer, NMIBC
Intravesical Drug Delivery System (Gem-iDRS) in NMIBCSiamak Daneshmand, MD2026Intravesical TherapyChemotherapyClinical TrialsNMIBC
Management of High Risk NMIBC—What’s New in Intravesical TherapyJodi K. Maranchie, MD, FACS2026Intravesical TherapyChemotherapy, Immunotherapy, Targeted TherapyBladder Preservation, Clinical TrialsNMIBC
Beyond Cancer: Breaking Down Bladder Cancer SurvivorshipJennifer Gomez, MMS, PA-C2025SurveillanceReconstructionBladder PreservationNMIBC
Session 4 Panel DiscussionTyler F. Stewart, MD2025Intravesical TherapyChemotherapy, Immunotherapy, TrimodalityBladder Preservation, Clinical TrialsNMIBC
Metastatic Bladder Cancer: Novel TherapiesTian Zhang, MD, MHS, FASCO2025Systemic TherapyImmunotherapy, Targeted TherapyMolecular Profiling, Clinical TrialsMetastatic
Case PresentationShilpa Gupta, MD2025Systemic TherapyChemotherapy, Immunotherapy, ADCMolecular Profiling, Bladder Preservation, Clinical TrialsMIBC
Neoadjuvant and Adjuvant Treatment for the Management of Upper Tract DiseaseShilpa Gupta, MD2025Systemic TherapyChemotherapy, ImmunotherapyClinical Trials
Management of Upper Tract Urothelial CarcinomaYair Lotan, MD2025SurgeryChemotherapy, Targeted Therapy, ReconstructionBladder PreservationMIBC
Upper Tract versus Lower Tract: Is There a Biological Difference?Donna E. Hansel, MD, PhD2025SurveillanceVariant Histology, Molecular ProfilingMIBC
Case PresentationSima P. Porten, MD, MPH, FACS2025Systemic TherapyChemotherapy, Immunotherapy, ADC, TrimodalityMolecular Profiling, Bladder Preservation, Clinical TrialsMIBC
Future Role for Local Therapy Following Successful Treatment of Metastatic Urothelial CarcinomaNima Almassi, MD2025SurgeryChemotherapy, Immunotherapy, ReconstructionBladder Preservation, Clinical TrialsMetastatic
Bladder Preservation: Post-Chemotherapy Immunotherapy for MIBCSima P. Porten, MD, MPH, FACS2025Systemic TherapyChemotherapy, Immunotherapy, ADCMolecular Profiling, Bladder Preservation, Clinical TrialsMIBC
Combined Modality Therapy for Localized Urothelial CarcinomaAmirali Salmasi, MD, MSCR2025RadiationChemotherapy, Immunotherapy, TrimodalityBladder Preservation, Clinical TrialsMIBC
Session 4 Panel Discussion: Radical Surgical Approaches to Bladder CancerBernard H. Bochner, MD, FACS2025Intravesical TherapyChemotherapy, Immunotherapy, Targeted Therapy, ADC, TrimodalityMolecular Profiling, Bladder Preservation, Clinical TrialsBladder Cancer, NMIBC
Surgical Quality, Urinary Diversion, and QOL Considerations for Invasive Bladder CancerBernard H. Bochner, MD, FACS2025SurgeryReconstructionBladder PreservationMIBC
Case PresentationRobert Dreicer, MD, MS, MACP, FASCO2025
Session 1 Panel Discussion: Pathology, Etiology, and Diagnosis of Urothelial CancerYair Lotan, MD2025
Adjuvant Therapy for Muscle-Invasive Urothelial CarcinomaGuru P. Sonpavde, MD2025Systemic TherapyChemotherapy, ImmunotherapyMolecular Profiling, Clinical TrialsMIBC
Intermediate Risk: Differences in Trial Designs Compared to High-Risk Disease, Comparisons, and Justifying ToxicityVignesh T. Packiam, MD2025Intravesical TherapyChemotherapy, Immunotherapy, Targeted TherapyMolecular Profiling, Clinical TrialsNMIBC
INLEXZO™ J Code UpdateDavid S. Morris, MD, FACS2026Intravesical TherapyChemotherapyClinical TrialsNMIBC
First-Line Therapy for Metastatic Locally Unresectable Urothelial CarcinomaDaniel P. Petrylak, MD2025Systemic TherapyChemotherapy, Immunotherapy, ADCClinical TrialsMetastatic
Selection and Sequencing: Optimizing Therapy for Relapsed/Refractory Metastatic Urothelial CancerArlene O. Siefker-Radtke, MD2025Systemic TherapyChemotherapy, Immunotherapy, Targeted Therapy, ADCMetastatic
Neoadjuvant Therapy: State-of-the-Art, Selection of Regimen, and Future TherapyGopakumar V. Iyer, MD2025Systemic TherapyChemotherapy, Immunotherapy, ADCMolecular Profiling, Bladder Preservation, Clinical TrialsMIBC
Bladder Sparing Strategies: Preserving Organ Function While Ensuring Oncologic ControlBrent Rose, MD2025
Perioperative Systemic Therapy Adjuvant IO: Integrating Systemic Treatments with Surgical ManagementNicolaos J. Palaskas, MD, PhD2025
How to Move Ahead in BCG-Unresponsive Disease: Selecting Initial Treatment, Sequences, and When is Enough Enough?Piyush K. Agarwal2025Intravesical TherapyChemotherapy, Immunotherapy, Targeted Therapy, ADCClinical TrialsNMIBC
Therapeutic Perioperative Decision-Making for Muscle-Invasive Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2025Systemic TherapyChemotherapy, Immunotherapy, ADCMolecular Profiling, Bladder Preservation, Clinical TrialsMIBC
Improving Sexual Functional Outcomes In MIBC-Nerve Sparing, Organ Preservation, and Other Quality Of Life ConsiderationsJohn W. Tillett, MD, FACS2025SurgeryReconstructionBladder PreservationMIBC
Frontline Systemic Treatment for Metastatic Disease: Optimizing First-Line Systemic Approaches for Advanced Urothelial CancerNicolaos J. Palaskas, MD, PhD2025
Gender Disparities in the Diagnosis of Urothelial CarcinomaDonna E. Hansel, MD, PhD2025SurveillanceVariant Histology, Molecular ProfilingMIBC
High-Risk NMIBC: Is BCG Still the Best Option?Neal D. Shore, MD, FACS2025Intravesical TherapyImmunotherapyClinical TrialsNMIBC
The Role of White Light Enhancements and AI-Based CystoscopyYair Lotan, MD2025SurgeryBladder Preservation, Clinical TrialsNMIBC
Molecular Changes in Bladder CancerDonna E. Hansel, MD, PhD2025Systemic TherapyTargeted Therapy, ADCVariant Histology, Molecular ProfilingMIBC
Biomarkers For Localized Disease: Are Molecular Predictive Markers Ready For Prime-Time Therapy Decisions?Tyler F. Stewart, MD2025
Intravesical Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC): Innovative Approaches to Preventing Progression and RecurrenceAmirali Salmasi, MD, MSCR2025Intravesical TherapyChemotherapy, Immunotherapy, Targeted TherapyMolecular Profiling, Clinical TrialsNMIBC
Perioperative Chemotherapy for Upper Tract Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2025
Current State of Neoadjuvant Chemotherapy in Urothelial CancersBenjamin W. Rush, MD2025
Perioperative Systemic Therapy: Perioperative ImmunotherapyTyler F. Stewart, MD2025
Therapies Beyond BCG for NMIBCBrant A. Inman, MD, MS, FRCSC2025
Bladder Sparing Methods in Muscle-Invasive Bladder CancerBrant A. Inman, MD, MS, FRCSC2025
Management of Muscle-Invasive Bladder Cancer: Paradigm Shift?Robert Dreicer, MD, MS, MACP, FASCO2025
Microbiome in Bladder CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Future of PathologyAdam Cole, MD, FS2025
Immunotherapy for Bladder CancerSteven E. Finkelstein, MD, DABR, FACRO2025
Microbiome and CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Bladder Sparing Tri-Modality Therapy Updates 2025Daniel A. Hamstra, MD, PhD, FASTRO, FASCO2025
What’s in the Pipeline for Bladder Cancer Management in 2026?Seth P. Lerner, MD, FACS2025
Urodynamics With and Without the Use of FluoroscopyMary Y. Wang, DNP, CRNP2025
Bladder Cancer Risk Factors and PrevalenceAnne E. Lizardi, DNP, CRNP, RNFA2025
Bladder Cancer Current Treatment LandscapeAnne E. Lizardi, DNP, CRNP, RNFA2025
Bladder Cancer Evaluation and DiagnosisAnne E. Lizardi, DNP, CRNP, RNFA2025
WSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation StudyWayne G. Brisbane, MD2025
Prostate Cancer Detection Biomarkers, MRIAdam S. Kibel, MD2025
Role of Immunotherapy for Upper Tract UCGopakumar V. Iyer, MD2024
Bladder Cancer Journal Vol. 11, Issue 2 - April - June 2025Bladder Cancer Journal2025
Role of DNA Repair Mutations in Sensitivity to Cisplatin-based ChemotherapyGopakumar V. Iyer, MD2024
Grade Group 1 at Biopsy - Do We Need to Know More?John W. Davis, MD, FACS2025
Updates to Microhematuria: AUA and SUFU Guidelines Update 2025Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD2025
Neoadjuvant Chemo vs. I/0 vs. ADCsDaniel P. Petrylak, MD2024
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate CancerSteven J. Frank, MD, FACR, FABS, FASTRO2025
Intermediate-Risk NMIBC/BCG Naïve: Treatment of ChoiceLeonard G. Gomella, MD, FACS2025
Bladder Cancer Journal Vol. 11, Issue 1 - January - March 2025Bladder Cancer Journal2025
High-Risk/BCG Naïve: Treatment of ChoiceMichael A. O'Donnell, MD, FACS2024
Bladder Cancer Biomarkers: SurveillanceYair Lotan, MD2024
Highlights of NCCN/AUA Guidelines 2024Siamak Daneshmand, MD2024
Role of Systemic Therapies in NMIBCAmirali Salmasi, MD, MSCR2024
Role of CtDNA in Bladder CancerAlexandra Drakaki, MD, PhD2024
Role of PLND for High Risk Bladder CancerBernard H. Bochner, MD, FACS2024
Erdafitinib Update - Metastatic Urothelial CancerDaniel P. Petrylak, MD2024
UTUC Staging, Diagnosis, Intraureteralpelvis Therapy, Endoscopic ManagementJennifer A. Linehan, MD2024
BCG Unresponsive Intravesical TherapyPiyush K. Agarwal2024
Perioperative Chemotherapy for Upper Tract Urothelial CancerRobert Dreicer, MD, MS, MACP, FASCO2024
Changing Paradigm of First Line Therapy in Locally Advanced Metastatic Bladder CancerParminder Singh, MD2024
Counterpoint: Radical Cystectomy for Muscle Invasive Bladder CancerJuan J. Chipollini, MD, FACS2024
Point: Bladder Sparing Approach for Muscle Invasive Bladder CancerParminder Singh, MD2024
Immunotherapy in Prostate CancerSandy Srinivas, MD2024
Clinical Trials in MIBC and NMIBCDaniel P. Petrylak, MD2024
Updates in Radiotherapy for Bladder CancerDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2024
Updates in Advanced Urothelial CarcinomaNeda Hashemi, MD, FACOG2024
The Bespoke Future of Cancer CareLeonard G. Gomella, MD, FACS2024
Recurrent T1HG Bladder cancer after BCG: More Intravesical Therapy or Radical CystectomyFrances M. Alba, MD2024
Current State of the Art in Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder CancerJason A. Efstathiou, MD, DPhil2024
Updates on the Imaging for Urothelial CarcinomaDesencia E. Thomas, MD2024
Utilizing ctDNA in Bladder CancerLeonard G. Gomella, MD, FACS2024
Current Management of T1 High Grade Bladder CancerFrances M. Alba, MD2024
The Making of the Ileal Orthotopic Bladder Substitute with an Afferent Tubular Segment: In Memory of Prof. Urs StuderFiona C. Burkhard, MD2024
Innovations in Bladder Cancer: Strategies for Improving Outcomes Across the Disease ContinuumDaniel P. Petrylak, MD2024
Bladder Cancer Journal Vol. 10, Issue 2Bladder Cancer Journal2024
Therapy for High Risk NMIBCColin P. N. Dinney, MD2023
Imaging and Biomarkers in Patient Selection for Focal AblationEzekiel Becher, MD2024
Updates on the Latest Classifications of Urothelial CancersFrancisco G. La Rosa, MD2024
Obstacles to Optimal Outcomes for Patients Undergoing Radical CystectomyRaj S. Pruthi, MD, MHA, FACS2022
UPJO Management: Cut, Construct, or CheckBenjamin K. Canales, MD, MPH2023
Emergent Applications of Prostate Cancer Mapping with Artificial IntelligenceAlan Priester, PhD2024
Clinical Evaluation and Management of Men with Localized and Recurrent Prostate CancerJan Philipp Radtke, MD, MBA2024
Clinical Trial of STHLM3 and MRITobias Nordstrom, MD, PhD2024
Prostate Cancer Screening Practices in EuropeMonique Roobol, PhD, MSc2024
NCCN Guidelines for Early Detection of Prostate Cancer 2023Preston C. Sprenkle, MD2024
Multi-modality (MRI+PET) Imaging for Improved Detection of csPCDavid Margel, MD, PhD2024
PSMA in Metastatic Prostate Cancer: Imaging as BiomarkerLouise Emmett, MD, FAANMS, FRACP, MBChB2024
Precision Diagnostics and Emerging Treatment StrategiesDavid M. Nanus, MD2024
Novel Targeted Treatment and Its Integration with Precision DiagnosticsDaniel P. Petrylak, MD2024
Micro-ultrasound and MRI for Visualization of Prostate CancerWayne G. Brisbane, MD2024
Bladder Cancer Journal Vol. 10, Issue 1Bladder Cancer Journal2024
Bladder Cancer Journal Vol. 9, Issue 4Bladder Cancer Journal2023
Diagnosing Renal Masses: Do Advanced Imaging Techniques and Biomarkers Play an Important Role?Justin J. Badal, MD2023
Bladder Cancer Journal Vol. 9, Issue 3Bladder Cancer Journal2023
Bladder Cancer Journal Vol. 9, Issue 2Bladder Cancer Journal2023
Role of Circulating Tumor DNA and Adjuvant Therapy in Urothelial CarcinomaTyler F. Stewart, MD2023
Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery - ProT. Mike Hsieh, MD, MBA2023
NMIBC Trials for BCG Naive Patients: What is ExcitingJoshua J. Meeks, MD, PhD2022
Neoadjuvant or Adjuvant Therapy?Parminder Singh, MD2022
Fusion-guided Ablation with Koelis ProMap-FTNiranjan Nayar, MHA2023
Neoadjuvant Therapy for MIBC in the Genomic EraColin P. N. Dinney, MD2023
Open vs Robotic Cystectomy for Bladder CancerColin P. N. Dinney, MD2023
Earlier Use of Immune Checkpoint Inhibitors to Adjuvant and NMIBC: What Do We Do About Patients for Reinduction of Immune TreatmentGuru P. Sonpavde, MD2022
Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to DoSeth P. Lerner, MD, FACS2022
Use of the Cxbladder Monitor Urine Genomics Test for Surveillance of Patients with Non-Muscle-Invasive Bladder CancerDaniel Shoskes, MD, MSc, FRCSC2022
Bladder Cancer Journal Vol. 9, Issue 1Bladder Cancer Journal2023
Bladder Cancer Risk Stratification: Moving from the Old to the NewJoshua J. Meeks, MD, PhD2022
Controversies in NMIBC: Guidelines and BeyondSam S. Chang, MD, MBA2022
Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?Peter Black, MD, FACS, FRCSC2022
The Contribution of SWOG to Bladder Cancer Clinical TrialsSeth P. Lerner, MD, FACS2022
Risk-Adapted TURBTSeth P. Lerner, MD, FACS2022
Bladder Sparing Tri-Modal Therapy UpdatesDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2022
Obstacles to Optimal Outcomes for Patients Undergoing Radical CystectomyRaj S. Pruthi, MD, MHA, FACS2023
Immune Checkpoint InhibitorsDaniel P. Petrylak, MD2022
Bladder Cancer Journal Vol. 8, Issue 4Bladder Cancer Journal2022
Enhanced Techniques of NMIBC DetectionMark D. Tyson II, MD, MPH2022
Use of Biomarkers in NMIBC: What’s New and What Should We Use?Peter Black, MD, FACS, FRCSC2022
Biomarker Integration for Advanced Urothelial CarcinomaDonna E. Hansel, MD, PhD2022
Pathology of Urothelial CancersDonna E. Hansel, MD, PhD2022
What Should I Do About Micropapillae? Do I Treat it Differently than Standard?Donna E. Hansel, MD, PhD2022
Methods and Guidelines to Stage and Grade (Low vs. High) UTUC and How Should We TreatSeth P. Lerner, MD, FACS2022
FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial CancerParminder Singh, MD2022
Targeted Therapy Combined with Immune Checkpoint Therapy: Is This the Wave of the Future?Jean Heather Hoffman-Censits, MD2022
High Risk and Advanced Upper Tract Urothelial Carcinoma – Still a Role for SurgeryJennifer A. Linehan, MD2022
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the FutureJennifer A. Linehan, MD2022
Immune Checkpoint Inhibitors: Combination TherapyJean Heather Hoffman-Censits, MD2022
Immune Checkpoint Inhibitors: Managing Immune-related Side EffectsGuru P. Sonpavde, MD2022
The Use of Antibody-drug Conjugates in Treating Advanced Urothelial CancerDaniel P. Petrylak, MD2022
UTUC Is it Biologically DistinctDonna E. Hansel, MD, PhD2022
Industry Perspective - From Science to Clinical Utility: The Role of Cxbladder in the Diagnosis and Management of Bladder CancerTamer Aboushwareb, MD, PhD2022
Bladder Cancer Journal Vol. 8, Issue 3Bladder Cancer Journal2022
Bladder Cancer Journal Vol. 8, Issue 2Bladder Cancer Journal2022
Non-Muscle Invasive Bladder Cancer: Guidelines-Based ApproachRaj S. Pruthi, MD, MHA, FACS2022
Point-Counterpoint: Neoadjuvant Chemotherapy Prior to Cystectomy (Pro)Amirali Salmasi, MD, MSCR2022
Point-Counterpoint: Neoadjuvant Chemotherapy Prior to Cystectomy - ConAlan H. Bryce, MD2022
Updating the Definitions, Endpoints, and Clinical Trial Designs for Bladder CancerAmirali Salmasi, MD, MSCR2022
Bladder Cancer Journal Vol. 8, Issue 1Bladder Cancer Journal2022
When is Radical Cystectomy Indicated for NMIBC?Guilherme Godoy, MD, MS2022
Bladder-Sparing Trimodality TherapyDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2022
Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder CancerAmirali Salmasi, MD, MSCR2022
Industry Perspective: Developing the Most Sensitive Urine Test for Bladder CancerNam W. Kim, PhD2022
Managing NMIBC in the BCG Shortage EraSeth P. Lerner, MD, FACS2022
Neoadjuvant vs. Adjuvant vs. None - "Perioperative Therapy"A. Edward Yen, MD2022
Bladder Cancer Journal Vol. 7, Issue 4Bladder Cancer Journal2021
Panel Discussion – Focus on PSMAPhillip J. Koo, MD2021
Bladder Cancer Journal Vol. 7, Issue 3Bladder Cancer Journal2021
Current Status of PSMA DiagnosticsJérémie Calais, MD, PhD2021
Next Generation Imaging for Prostate CancerPhillip J. Koo, MD2021
Deciphering the Changing Landscape of Differential Delay in Cancer Diagnoses in Community Radiation and Medical OncologyMitchell O. Finkelstein2021
Urine Biomarkers for the Detection of Urothelial CarcinomaSiamak Daneshmand, MD2021
Blue Light vs. White Light Cystoscopy for NMIBCSanjay G. Patel, MD2021
A Review of AUA / SUO / ASTRO Guidelines for MIBCMichael S. Cookson, MD, MMHC2021
Bladder Cancer Journal Vol. 7, Issue 2Bladder Cancer Journal2021
Industry Perspective: The Role of URO17 â„¢ in the Diagnosis and Management of Bladder CancerJohn Cucci2021
Industry Perspective: Panel Discussion on Cxbladder Genomic Urine Test for Bladder CancerSiamak Daneshmand, MD2021
Bladder Cancer Journal Vol. 7, Issue 1Bladder Cancer Journal2020
Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder CancerRobert Dreicer, MD, MS, MACP, FASCO2021
Neoadjuvant Immune-Checkpoint Inhibition for Muscle-Invasive Bladder CancerPetros Grivas, MD, PhD2021
Bladder Cancer Journal Vol. 6, Issue 4Bladder Cancer Journal2020
Immunotherapy For Muscle Invasive Bladder CancerA. Edward Yen, MD2020
Bladder Cancer Journal Vol. 6, Issue 3Bladder Cancer Journal2020
PC Markers AlgorithmE. David Crawford, MD2020
Updates in Muscle Invasive Bladder CancerSiamak Daneshmand, MD2020
The First Tissue Engineered Neo-Urinary Conduit (NUC) Clinical Trial for Complete Organ Replacement: Successes, Pitfalls, ChallengesTrinity J. Bivalacqua, MD, PhD2020
Blue Light Cystoscopy: How Does It Fit into the Non-Muscle Invasive Bladder Cancer Guidelines?Jeffrey M. Holzbeierlein, MD2020
Bladder Cancer Journal Vol. 6, Issue 2Bladder Cancer Journal2020
ERAS Pathways in Radical CystectomyJeffrey M. Holzbeierlein, MD2020
Management of High-Grade T1 Bladder CancerJeffrey M. Holzbeierlein, MD2020
The Role of Immunonutrition in Bladder Cancer & the SIMMUNE Trial (S1600)Jeffrey M. Holzbeierlein, MD2020
Adaptive Immune Resistance to Intravesical BCG in NMIBC: Implications for Ongoing and Future BCG Unresponsive Clinical TrialsTrinity J. Bivalacqua, MD, PhD2020
Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder CancerJeffrey M. Holzbeierlein, MD2020
Bladder Cancer Journal Vol. 6, Issue 1Bladder Cancer Journal2020
BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder CancerDonald L. Lamm, MD, FACS2019
Robotic Cystectomy and ICUD for Muscle Invasive Bladder CancerSanjay G. Patel, MD2019
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial CarcinomaDaniel P. Petrylak, MD2020
FDA Approves Pembrolizumab for New Indication of NMIBCDaniel P. Petrylak, MD2020
Bladder Cancer Journal Vol. 5 Issue 4Bladder Cancer Journal2019
ESMO: Astellas, Seattle Genetics' Keytruda Combo Shrinks 71% of Bladder CancersDaniel P. Petrylak, MD2019
Bladder Cancer Journal Vol. 5 Issue 3Bladder Cancer Journal2019
Case-Based Panel Discussion: Muscle-Invasive Bladder CancerJennifer M. Taylor, MD, MPH2019
Prevalence of Criteria for Genetic Testing According to the National Comprehensive Cancer Network Guidelines in a Contemporary Cohort of Post-Prostatectomy Men with Intermediate and High-Risk Prostate Cancer: The Henry Ford Health System ExperienceDavid Utz2019
Case-Based Panel Discussion: Non-Muscle Invasive Bladder CancerJennifer M. Taylor, MD, MPH2019
Bladder Cancer Journal Vol. 5 Issue 2David Utz2019
Live-Primary Cell Phenotypic Biomarkers and Prostate Cancer PrognosisDavid M. Albala, MD2019
PT0 after NAC: Implications for Bladder Sparing and PrognosisLeonard G. Gomella, MD, FACS2019
Management of Adverse Pathology after Radical ProstatectomyJason A. Efstathiou, MD, DPhil2019
The Gold Standard for Bladder Cancer DetectionNeal D. Shore, MD, FACS2019
Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard?Seth P. Lerner, MD, FACS2019
Lymphadeneactomy in Invasive Bladder Cancer: Knowns and UnknownsSeth P. Lerner, MD, FACS2019
BCG Maintenance Should Be Less IntenseMichael S. Cookson, MD, MMHC2018
Debate: Neoadjuvant Chemotherapy Prior to Cystectomy | Con ArgumentMichael S. Cookson, MD, MMHC2018
Debate: Neoadjuvant Chemotherapy Prior to Cystectomy | Pro ArgumentDaniel P. Petrylak, MD2018
Thromboembolic Complications in Bladder CancerLeonard G. Gomella, MD, FACS2019
T1 Bladder CancerSeth P. Lerner, MD, FACS2019
Checkpoint Inhibitors for NMIBCDaniel P. Petrylak, MD2018
Can MR Imaging Help Triage Bladder Cancer Patients?John C. Chang, MD, PhD2018
Targeted Therapy for the Treatment of Advanced/Metastatic Urothelial CancerDaniel P. Petrylak, MD2019
Urinary Markers in NMIBC: What’s New?Sanjay G. Patel, MD2019
BCG Unresponsive DiseaseSanjay G. Patel, MD2019
Bladder Cancer Journal Vol. 5 Issue 1Bladder Cancer Journal2019
Bladder Cancer and ImmunotherapyJennifer M. Taylor, MD, MPH2018
Lymph Node Dissection During Radical Cystectomy – Current State of the ArtSeth P. Lerner, MD, FACS2018
Case Based Decision-Making for Treatment of MIBCSeth P. Lerner, MD, FACS2018
Bladder Cancer Journal Vol. 4 Issue 4Bladder Cancer Journal2018
Second-line Bladder Cancer Therapies When First Line Treatments FailJennifer M. Taylor, MD, MPH2018
Controversies in Non-Muscle Invasive Bladder CancerSiamak Daneshmand, MD2018
Updates on Immunotherapy for Bladder CancerDaniel P. Petrylak, MD2018
A Biodynamic Imaging Platform for Bladder CancerJeff Fensterer2018
Bladder Cancer Journal Vol. 4 Issue 3Bladder Cancer Journal2018
En Bloc TURB - More Than a Safe and Feasible Surgical TechniqueSalvatore Micali, MD2018
Bladder Cancer Journal Vol. 4 Issue 2Bladder Cancer Journal
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United StatesBladder Cancer Journal2018
Bladder Cancer Genetic Susceptibility. A Systematic ReviewBladder Cancer Journal2018
The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder CancerBladder Cancer Journal2018
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological VariantsBladder Cancer Journal2018
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional StudyBladder Cancer Journal2018
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell LinesBladder Cancer Journal2018
Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and PreventionBladder Cancer Journal2018
Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical CystectomyBladder Cancer Journal2018
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging TherapiesBladder Cancer Journal2018
Advanced Disease — A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2018
New Targets for Advanced Bladder CancerDaniel P. Petrylak, MD2018
Should Variant Histology Change Management of Bladder Cancer?Peter Black, MD, FACS, FRCSC2018
Neoadjuvant/ Adjuvant Chemotherapy—Are We Ready to Accept Neoadjuvant as the Gold Standard?Seth P. Lerner, MD, FACS2018
Basic Concepts in Bladder Cancer ImmunotherapyLeonard G. Gomella, MD, FACS2018
Basic Science Foundations of Bladder Cancer Diagnosis and TreatmentDan Theodorescu, MD, PhD2018
New Targets for the Treatment of Urothelial CancerDaniel P. Petrylak, MD2018
Perioperative Pathways: What We Know WorksPeter Black, MD, FACS, FRCSC2018
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelinesSam S. Chang, MD, MBA2018
BCG Unresponsive Disease: A Roadmap for Drug Development and Integration of Novel TherapiesSeth P. Lerner, MD, FACS2018
Enhanced Techniques of Non-Muscle Invasive Bladder Cancer DetectionMichael S. Cookson, MD, MMHC2018
Urine Markers for Bladder CancerPeter Black, MD, FACS, FRCSC2018
Robotic Cystectomy Versus Open Cystectomy: What Do We Know?Sam S. Chang, MD, MBA2018
Barriers to Clinical Trials for Non-Muscle Invasive Bladder CancerAshish M. Kamat, MD, MBBS2018
Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder CancerBladder Cancer Journal2018
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-AnalysisBladder Cancer Journal2018
Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder CancerBladder Cancer Journal2018
Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7Bladder Cancer Journal2018
Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and EnablersBladder Cancer Journal2018
Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T MutationBladder Cancer Journal2018
Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic ReviewBladder Cancer Journal2018
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder CancerBladder Cancer Journal2018
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder CancerBladder Cancer Journal2018
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder CancerBladder Cancer Journal2018
Perioperative Management of the Radical Cystectomy PatientErik P. Castle, MD, FACS2017
Immunotherapeutic Agents in Metastatic Bladder CancerAlan H. Bryce, MD2017
Can the DECIPHER Marker Predict Chemotherapy?Robert Abouassaly, MD, MS2017
The DECIPHER Marker Can Predict ChemotherapyAlan H. Bryce, MD2017
BCG Failure: BCG Maintenance Should be Less IntenseMichael S. Cookson, MD, MMHC2017
BCG Maintenance - Full SWOG Course - Pro ArgumentErik P. Castle, MD, FACS2017
Difficult Issues in Non Muscle Invasive Bladder CancerMichael S. Cookson, MD, MMHC2017
BCG Failure: Defining and Managing Difficult PatientsMichael S. Cookson, MD, MMHC2017
Urinary Molecular Marker Tests in Bladder Cancer: An Overview of CxbladderSiamak Daneshmand, MD2017
Prevalence of Clostridium Difficile Infection in Patients After Radical Cystectomy and Neoadjuvant ChemotherapyBladder Cancer Journal2017
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder CancerBladder Cancer Journal2017
Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data BaseBladder Cancer Journal2017
Bladder Cancer Recovery Pathways: A Systematic ReviewBladder Cancer Journal2017
Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder CancerBladder Cancer Journal2017
Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder CancerBladder Cancer Journal2017
Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?Bladder Cancer Journal2017
Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the LiteratureBladder Cancer Journal2017
Quality Indicators in Radical CystectomySeth P. Lerner, MD, FACS2017
Perioperative Pathways: What We Know WorksPeter Black, MD, FACS, FRCSC2017
Thromboembolic Complications in Bladder CancerJehonathan H. Pinthus, MD, PhD, FRCSC2017
Robotic Cystectomy Versus Open Cystectomy: Do We Really Need to Discuss?Sam S. Chang, MD, MBA2017
Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder CancerDaniel P. Petrylak, MD2017
Precision Medicine and Advanced Bladder Cancer: Where Are We Today?Dan Theodorescu, MD, PhD2017
Checkpoint InhibitorsDaniel P. Petrylak, MD2017
Neoadjuvant and Adjuvant Chemotherapy in Bladder CancerNeal D. Shore, MD, FACS2017
Basic Science in Bladder Cancer: What a Practicing Urologist Needs to Know in 2017Dan Theodorescu, MD, PhD2017
BCG Unresponsive Non-Muscle Invasive Bladder CancerSeth P. Lerner, MD, FACS2017
Enhanced Technique Endoscopic Visualization in NMIBCMichael S. Cookson, MD, MMHC2017
Urine Markers for Bladder CancerPeter Black, MD, FACS, FRCSC2017
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelinesSam S. Chang, MD, MBA2017
Biomarkers in Genitourinary CancersE. David Crawford, MD2015
Bladder Cancer: Advances in Diagnosis and Clinical CareSeth P. Lerner, MD, FACS2015